Date: Thursday, December 13, 2018
Time: 9:00 AM EST
Developing new drugs is a lengthy, expensive, high-risk process. Only 14% of drugs that get to the phase of clinical trials eventually win approval from the FDA, and the cost to bring a drug from R&D to marketing averages around $3 billion. Even after launch, close to half of new drugs underperform compared to analyst expectations.
To better understand the decisions and processes underlying these outcomes—and to help the industry improve its success rate—Catalent and BioPharma Dive's Brand Studio conducted an exclusive survey of pharmacy industry professionals.
Pharma execs identified the top success factors for new drugs, revealed specific issues that hurt new treatment performance, and suggested practical solutions for optimizing the drug development process.
Join this webinar to explore the survey data and extract knowledge that will help you design better drugs.
Cornell Stamoran, Ph.D.
Vice President, Strategy & Govt. Affairs
Catalent Pharma Solutions